CLEVELAND, April 18, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, has begun treating patients with the MRIdian System, the world's first and only clinical MRI-guided radiation therapy system.
The first two Sylvester cancer patients were treated using the system over the past few days. The cancer center is currently ramping up the use of the MRIdian System and doctors there are excited to be able to provide this world-class technology to their patients.
"The ability to view the tumor and normal tissues in real-time using MRI-guidance is a huge advance in radiation therapy which we expect to benefit patients through improvements in tumor control and reduced toxicity," said Alan Pollack, M.D., Ph.D., Radiation Oncology Chair at Sylvester. "We're proud to offer this advanced cancer treatment to patients within Florida and beyond."
MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered. MRIdian is the only system in the world that can provide continuous soft-tissue imaging during radiation treatment. This means that, for the first time, doctors are able to see the tumor they are treating continuously, enabling personalized and truly adaptive radiation therapy.
"Sylvester Comprehensive Cancer Center at the University of Miami is renowned for its research and cutting-edge treatments," said Chris A. Raanes, president and CEO of ViewRay Incorporated. "We are delighted that they see how MRIdian can help cancer patients."
In addition to Sylvester, the MRIdian system is treating patients at leading cancer centers around the world including the UCLA Jonsson Comprehensive Cancer Center in Los Angeles; Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine in in St. Louis, Mo.; the University of Wisconsin Carbone Cancer Center in Madison, Wis.; and Seoul National University Hospital in Korea. MRIdian is being used to treat many different types of cancers including those of the lung, liver, prostate, breast, bladder, and head and neck.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/treatment-with-viewrays-mri-guided-radiation-therapy-now-available-on-the-us-east-coast-300252578.html
SOURCE ViewRay, Inc.